
On Monday, November 25, quotes on the small-cap biotech company Cassava Sciences plunged almost 84% after the company reported that its Alzheimer’s treatment had failed in a clinical trial. Details On Monday, Cassava Sciences stock lost almost 84% on the Nasdaq to $4.30 per share. This marked the biggest percentage…